Gsk Share Discussion Threads

[supermarky] 23/2/2024 08:36

I must say the share price movement looks very encouraging. seems to be having a little rest before the next leg up.

[tradermichael] 23/2/2024 07:48

Ask abdullla!

[zho] 22/2/2024 16:14

Yes, xd 16p today, I think.

[tradermichael] 22/2/2024 09:14

British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus’s progression.

[rikky72] 21/2/2024 12:01

That's because they are not..

[alibizzle] 21/2/2024 11:07

None of this sounds true

[rikky72] 21/2/2024 10:58

And she's taken out a massive short on the company too under a pseudonym..

[abdullla] 21/2/2024 09:53

She sold because she had inside knowledge of today's and tomorrow's ex-div share price drop,nothing new

[patientcapital] 20/2/2024 08:03

She sold to raise funds to meet the tax liability but has managed to retain 157,636 shares from the award.

[alibizzle] 20/2/2024 07:51

I hope she hasn't been tipped off about a so crash ! Strange she would miss dividend, she would have made 50k!

[tradermichael] 20/2/2024 07:25

Looks like Emma will miss out on the dividend .....

GSK plc (LON:GSK) insider Emma Walmsley sold 139,792 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.94), for a total value of £2,317,751.36 ($2,927,192.93).

[tradermichael] 18/2/2024 15:19

xdiv on Thursday 22nd ..... 16p/share ...... ;o)

[tradermichael] 15/2/2024 08:41

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

[anhar] 14/2/2024 11:35

If only it were that simple to make money TM. Personally I think TA is a load of boll but if anyone can make long term good rewards from repeated short term TA trading then fine. I suspect though that it's only a tiny minority of those attempting to do so.

[tradermichael] 14/2/2024 11:21

However,

Technical analysts use support and resistance levels to identify price points on a chart where the probabilities favour a pause or reversal of a prevailing trend.

Support occurs where a downtrend is expected to pause due to a concentration of demand.

Resistance occurs where an uptrend is expected to pause temporarily, due to a concentration of supply.

Market psychology plays a major role as traders and investors remember the past and react to changing conditions to anticipate future market movement.

Support and resistance areas can be identified on charts using trendlines and moving averages.

[montyhedge] 14/2/2024 09:03

Glaxo part of GS so called Granola stocks, Glaxo, Roche, Astra Nordisk, etc. Glaxo will be 1950p, but for me Novo Nordisk is the big hitter, fat buster drug, making billions, doubler I reckon.

[drk1] 14/2/2024 08:30

It will, but by the looks of things, with little resistance to 18, the share price is keen to get there pretty quick!

[beergut] 13/2/2024 10:19

Just looked back 20 years at the chart and looks like breaking 18 will be tough

[supermarky] 13/2/2024 10:12

having a little rest before moving on up

[tradermichael] 13/2/2024 10:09

The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years.

Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for belantamab mafodotin, (known as Blenrep for short), the drug giant's treatment for the blood disease myeloma.

"Our upgrade is based not only on Blenrep’s underappreciated revenue potential but also the cumulative impact of the multiple incremental positives ranging from Zantac liability outlook, RSV/ Shingrix, astute business development, and increasingly positive ViiV outlook post dolutegravir loss of exclusivity," Citi said in a note to clients.

Its upbeat stance on Blenrep stems from the "compelling" results from GSK's DREAMM-7 phase III clinical trial. Assuming the next set of study results are positive, then the drug "has a significant role for at least the next five years as a standard of care for refractory myeloma patients, particularly for older patients that are either poor candidates for CAR-T or bispecifics, or who receive their treatment within the community".

In early trade, the shares were up 14.34p at 1,640.74p. Citi reckons the stock is worth £21 (up from £17).

[igoe104] 13/2/2024 09:57

Here the link

[montyhedge] 13/2/2024 08:15

That's the first time in 7 years Citi has a buy on GSK, 2100p target.

[dplewis1] 13/2/2024 07:57

Citigroup raises target to 2100p from 1700p